Peptide Linker Antibody-Drug Conjugate Design
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody-drug conjugate (ADC) technologies face challenges in optimizing the configuration of ADCs for enhanced efficacy and specificity, particularly in the attachment of active agents to antibodies through linkers that ensure site-specific and mild attachment while maintaining stability and targeted drug release.
Innovation Solution
The development of an antibody-drug conjugate comprising a peptide sequence of amino acids with at least two active agents covalently coupled to the side chains, utilizing a linker that includes a self-immolative group and an O-substituted oxime, where the oxygen atom is linked to the active agents and the carbon atom is linked to the antibody, facilitating controlled drug release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If active agents are attached to antibodies through conventional linkers, then the ADC can be formed, but the attachment lacks site-specificity and precision in drug release
Solution Approach 1:
The linker is divided into distinct functional segments: a peptide sequence for site-specific attachment to the antibody, a self-immolative group for controlled drug release, and an O-substituted oxime for stable conjugation. This segmentation allows each component to perform its specific function independently, achieving precise site-specific attachment while maintaining manageable structural complexity.
Solution Approach 2:
The self-immolative group acts as an intermediary between the stable antibody-linker conjugation and the drug release mechanism. It remains stable during circulation but undergoes spontaneous decomposition under specific intracellular conditions to release the active agent, thereby mediating between the need for stable attachment and controlled release.
2Reliability
If the linker uses a self-immolative group for controlled drug release, then the therapeutic efficacy is improved, but the linker structure becomes more complex
Solution Approach 1:
The self-immolative group performs the drug release function autonomously without requiring external enzymes or additional cellular machinery. Upon entering the target cell, it spontaneously decomposes through intrinsic chemical instability under specific conditions (such as low pH or specific redox environments), reliably releasing the active agent through self-service rather than requiring complex external control mechanisms.
3Productivity
If multiple active agents are covalently coupled to the linker, then the therapeutic efficacy is enhanced, but the risk of collateral damage to healthy cells increases
Solution Approach 1:
The peptide sequence portion of the linker provides local quality by enabling site-specific attachment to particular amino acid residues on the antibody surface. This localized precision ensures that the multiple active agents are positioned and released in a controlled manner at the target site, maximizing therapeutic efficacy while minimizing off-target effects on healthy cells through the specificity of the peptide-antibody interaction.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This configuration enhances the targeted delivery and release of active agents, improving the therapeutic efficacy of ADCs by ensuring precise attachment and controlled release of drugs, thereby minimizing collateral damage to healthy cells and maximizing cancer cell targeting.
Implementation Method 1
The antibody-drug conjugate may comprise a self-immolative group, preferably two-self-immolative groups
Implementation Method 2
The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agents; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody
Data Source
AI summary
In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and at least two active agents. In preferred embodiments, the linker comprises a peptide sequence of a plurality of amino acids, and at least two of the active agents are covalently coupled to side chains of the amino acids. The antibody-drug conjugate may comprise a self-immolative group, preferably two-self-immolative groups. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.